The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin

Neurobiology of Disease

Volumn 81, Issue , 2015, Pages 49-65

  Peters, Douglas G ^a   Connor, James R ^a   Meadowcroft, Mark D ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

AD; Alzheimer's disease; Amyloidogenesis; Beta amyloid; Dyshomeostasis; Iron; Metallosis; Pathology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CALCIUM CHANNEL L TYPE; CD71 ANTIGEN; FERRITIN; GLUTATHIONE; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; AMYLOID BETA PROTEIN;

AGING; ALZHEIMER DISEASE; AMYLOID CASCADE HYPOTHESIS; AMYLOID PLAQUE; AMYLOIDOSIS; ASTROCYTE; BRAIN IRON ACCUMULATION; BRAIN LEVEL; BRAIN PERFUSION; CELL FUNCTION; GENETIC TRANSCRIPTION AND TRANSLATION; HUMAN; HYPOTHESIS; IRON ABSORPTION; IRON DYSHOMEOSTASIS; IRON METABOLISM DISORDER; IRON STORAGE; IRON TRANSPORT; MICROGLIA; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; VASCULAR AMYLOIDOSIS; COMPLICATION; HOMEOSTASIS; METABOLISM; PHYSIOLOGY; PLAQUE, AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HOMEOSTASIS; HUMANS; IRON; PLAQUE, AMYLOID;

EID: 84950311757     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.08.007     Document Type: Review

References (251)

1. Adamcio B., Sperling S., Hagemeyer N., Walkinshaw G., Ehrenreich H. Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice. Behav. Brain Res. 2010, 208:80-84.
2. Agosta F., et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 2011, 258:853-863.
3. Agosta F., et al. Myeloid microvesicles in cerebrospinal fluid are associated with myelin damage and neuronal loss in mild cognitive impairment and Alzheimer disease. Ann. Neurol. 2014, 76:813-825.
4. 2+ from ferritin by the physiologically-occurring Cu(I)-glutathione complex. Bioorg. Med. Chem. 2011, 19:534-541.
5. Andrews N.C. The iron transporter DMT1. Int. J. Biochem. Cell Biol. 1999, 31:991-994.
6. Austin S.A., Santhanam A.V., Katusic Z.S. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res. 2010, 107:1498-1502.
7. Avramovich-Tirosh Y., Bar-Am O., Amit T., Youdim M.B.H., Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res. 2010, 7:300-306.
8. Ayton S., Lei P., Bush A.I. Metallostasis in Alzheimer's disease. Free Radic. Biol. Med. 2013, 62:76-89.
9. Ayton S., et al. Ceruloplasmin and β-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radic. Biol. Med. 2014, 69:331-337.
10. Bandyopadhyay S., et al. Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for Down syndrome and Alzheimer's disease. PLoS One 2013, 8:14.
11. Barber M.F., Elde N.C. Nutritional immunity. Escape from bacterial iron piracy through rapid evolution of transferrin. Science 2014, 346:1362-1366.
12. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology 2002, 27:672-683.
13. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 2004, 25:5-18.
14. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32:1341-1371.
15. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 2004, 1012:224-236.
16. Becerril-Ortega J., Bordji K., Freret T., Rush T., Buisson A. Iron overload accelerates neuronal amyloid-beta production and cognitive impairment in transgenic mice model of Alzheimer's disease. Neurobiol. Aging 2014, 35:2288-2301.
17. Bélanger M., Allaman I., Magistretti P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011, 14:724-738.
18. Bodovitz S., Falduto M.T., Frail D.E., Klein W.L. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J. Neurochem. 1995, 64:307-315.
19. Bostanci M.Ö., Bagirici F. Blocking of L-type calcium channels protects hippocampal and nigral neurons against iron neurotoxicity: the role of L-type calcium channels in iron-induced neurotoxicity. Int. J. Neurosci. 2013, 123:876-882.
20. Bousejra-ElGarah F., Bijani C., Coppel Y., Faller P., Hureau C. Iron(II) binding to amyloid-beta, the Alzheimer's peptide. Inorg. Chem. 2011, 50:9024-9030.
21. Bush A.I., et al. Evidence for APOE protecting against brain iron overload. Alzheimers Dement. 2014, 10:P878.
22. Busi M.V., Gomez-Casati D.F. Exploring frataxin function. IUBMB Life 2012, 64:56-63.
23. Caldeira G.L., Ferreira I.L., Rego A.C. Impaired transcription in Alzheimer's disease: key role in mitochondrial dysfunction and oxidative stress. J. Alzheimers Dis. 2013, 34:115-131.
24. Carroll J.C., et al. Sex differences in β-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res. 2010, 1366:233-245.
25. Castellano J.M., et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
26. Chan A., Shea T.B. Dietary and genetically-induced oxidative stress alter tau phosphorylation: influence of folate and apolipoprotein E deficiency. J. Alzheimers Dis. 2006, 9:399-405.
27. Chávez J.C., Agani F., Pichiule P., LaManna J.C. Expression of hypoxia-inducible factor-1alpha in the brain of rats during chronic hypoxia. J. Appl. Physiol. 2000, 89:1937-1942.
28. Chen J.-H., Shahnavas S., Singh N., Ong W.-Y., Walczyk T. Stable iron isotope tracing reveals significant brain iron uptake in adult rats. Metallomics 2013, 5:167-173.
29. Cheng D., et al. Type 2 diabetes and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2011, 31:424-430.
30. Chih C.-P., Roberts E.L. Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis. J. Cereb. Blood Flow Metab. 2003, 23:1263-1281.
31. Chouraqui E., et al. Deferoxamine blocks death induced by glutathione depletion in PC 12 cells. Neurotoxicology 2013, 37:221-230.
32. Clavaguera F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
33. Coby A.J., Picardal F., Shelobolina E., Xu H., Roden E.E. Repeated anaerobic microbial redox cycling of iron. Appl. Environ. Microbiol. 2011, 77:6036-6042.
34. Cohen S.I.A., et al. Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism. PNAS 2013, 110:9758-9763.
35. Collingwood J.F., et al. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J. Alzheimers Dis. 2008, 14:235-245.
36. Conejero-Goldberg C., et al. APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. Mol. Psychiatry 2014, 19:1243-1250.
37. Connor J.R., Benkovic S.A. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann. Neurol. 1992, 32:S51-S61. (Suppl.).
38. Connor J.R., Menzies S.L. Relationship of iron to oligodendrocytes and myelination. Glia 1996, 17:83-93.
39. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimers-disease. J. Neurosci. Res. 1992, 31:327-335.
40. Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res. 1992, 31:75-83.
41. Connor J.R., et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011, 134:959-968.
42. Corrigan F., et al. Characterisation of the effect of knockout of the amyloid precursor protein on outcome following mild traumatic brain injury. Brain Res. 2012, 1451:87-99.
43. Dahms S.O., et al. Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain. J. Mol. Biol. 2012, 416:438-452.
44. Dallman P.R. Brain iron in the rat: extremely slow turnover in normal rats may explain long-lasting effects of early iron deficiency. J. Nutr. 1977, 107:1075-1081.
45. Damoiseaux J.S., et al. Gender modulates the APOE ε4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J. Neurosci. 2012, 32:8254-8262.
46. Dasari B., Prasanthi J.R., Marwarha G., Singh B.B., Ghribi O. The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol. 2010, 10:22.
47. Davalos D., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
48. De Calignon A., et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
49. Deibel M.A., Ehmann W.D., Markesbery W.R. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 1996, 143:137-142.
50. Den Dunnen W.F.A., et al. No disease in the brain of a 115-year-old woman. Neurobiol. Aging 2008, 29:1127-1132.
51. Desagher S., Glowinski J., Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J. Neurosci. 1996, 16:2553-2562.
52. Ding B., et al. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Reson. Imaging 2009, 29:793-798.
53. Doens D., Fernández P.L. Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. J. Neuroinflammation 2014, 11:48.
54. Dong J., et al. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13313-13318.
55. Duce J.A., et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142:857-867.
56. Everett J., et al. Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide b-amyloid (1-42). J. R. Soc. Interface 2014, 11.
57. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
58. Farris W., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
59. Fitzner D., et al. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J. Cell Sci. 2011, 124:447-458.
60. Flicek P., et al. Ensembl 2014. Nucleic Acids Res. 2014, 42:D749-D755.
61. Ford G.C., et al. Ferritin: design and formation of an iron-storage molecule. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1984, 304:551-565.
62. Fujita T., Tozaki-Saitoh H., Inoue K. P2Y1 receptor signaling enhances neuroprotection by astrocytes against oxidative stress via IL-6 release in hippocampal cultures. Glia 2009, 57:244-257.
63. Galbete J.L., et al. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 2000, 348(Pt 2):307-313.
64. Ghribi O., Golovko M.Y., Larsen B., Schrag M., Murphy E.J. Deposition of iron and β-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006, 99:438-449.
65. Grundke-Iqbal I., et al. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. 1990, 81:105-110.
66. Gu Z., Nakamura T., Lipton S.A. Redox reactions induced by nitrosative stress mediate protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Mol. Neurobiol. 2010, 41:55-72.
67. Guo J.L., Lee V.M.Y. Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 2011, 286:15317-15331.
68. Guo C., et al. Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 2013, 62:165-172.
69. Guo C., et al. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 2013, 34:562-575.
70. Ha C., Ryu J., Chan B.P. Metal ions differentially influence the aggregation and deposition of Alzheimer's β-amyloid on a solid template. Biochemistry 2007, 46:6118-6125.
71. Hafezi-Moghadam A., Thomas K.L., Wagner D.D. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol. 2007, 292:C1256-C1262.
72. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain 1958, 3:41-51.
73. Hallgren B., Sourander P. The non-haemin iron in the cerebral cortex in Alzheimer's disease. J. Neurochem. 1960, 5:307-310.
74. Han J., et al. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One 2011, 6:e23800.
75. Hanger D.P., et al. Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated 1991, 275:99-104.
76. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956, 11:298-300.
77. Harrison P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta Bioenerg. 1996, 1275:161-203.
78. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
79. Heni M., et al. Insulin promotes glycogen storage and cell proliferation in primary human astrocytes. PLoS One 2011, 6:e21594.
80. Heuer E., Rosen R.F., Cintron A., Walker L.C. Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr. Pharm. Des. 2012, 18:1159-1169.
81. Hirtz D., et al. How common are the 'common' neurologic disorders?. Neurology 2007, 68:326-337.
82. Hohnholt M.C., Dringen R. Uptake and metabolism of iron and iron oxide nanoparticles in brain astrocytes. Biochem. Soc. Trans. 2013, 41:1588-1592.
83. Holmes-Hampton G.P., et al. Changing iron content of the mouse brain during development. Metallomics 2012, 4:761-770.
84. Honda S., et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J. Neurosci. 2001, 21:1975-1982.
85. Horowitz M.P., Greenamyre J.T. Mitochondrial iron metabolism and its role in neurodegeneration. J. Alzheimers Dis. 2010, 20.
86. Hsu C.C., Wahlqvist M.L., Lee M.S., Tsai H.N. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J. Alzheimers Dis. 2011, 24:485-493.
87. Hu C.-J., Wang L.-Y., Chodosh L.A., Keith B., Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 2003, 23:9361-9374.
88. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
89. Huang X.-T., et al. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease. Neurobiol. Aging 2014, 35:1045-1054.
90. Iliff J.J., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci. Transl. Med. 2012, 4:147ra111.
91. Ittner L.M., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
92. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
93. Jack C.R., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
94. Jamieson S.E., et al. Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease. Neurosci. Lett. 2005, 374:124-128.
95. Jayakumar R., et al. Red cell perturbations by amyloid β-protein. Biochim. Biophys. Acta Gen. Subj. 2003, 1622:20-28.
96. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B.H. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 1990, 2:327-340.
97. Jiao Y., et al. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med. 2006, 40:1152-1160.
98. Jomova K., Vondrakova D., Lawson M., Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 2010, 345:91-104.
99. Joseph-Mathurin N., et al. Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol. Aging 2013, 34:2613-2622.
100. Joshi P., et al. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death Differ. 2014, 21:582-593.
101. Kanekiyo T., Xu H.X., Bu G.J. ApoE and A beta in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
102. Kanninen K., et al. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16505-16510.
103. Karczewska-Kupczewska M., et al. The influence of insulin infusion on the metabolism of amyloid b peptides in plasma. Alzheimers Dement. 2013, 9:400-405.
104. Karelson E., et al. The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem. Res. 2001, 26:353-361.
105. Kaufmann M.R., et al. Dysregulation of hypoxia-inducible factor by presenilin/γ-secretase loss-of-function mutations. J. Neurosci. 2013, 33:1915-1926.
106. Keir G., Tasdemir N., Thompson E.J. Cerebrospinal fluid ferritin in brain necrosis: evidence for local synthesis. Clin. Chim. Acta 1993, 216:153-166.
107. Kennedy M.C., Emptage M.H., Dreyer J.L., Beinert H. The role of iron in the activation-inactivation of aconitase. J. Biol. Chem. 1983, 258:11098-11105.
108. Khan A., Dobson J.P., Exley C. Redox cycling of iron by Abeta42. Free Radic. Biol. Med. 2006, 40:557-569.
109. Khurana V., et al. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet. 2010, 6:e1001026.
110. Kidane T.Z., Sauble E., Linder M.C. Release of iron from ferritin requires lysosomal activity. Am. J. Physiol. Cell Physiol. 2006, 291:C445-C455.
111. Kiko T., et al. Amyloid β levels in human red blood cells. PLoS One 2012, 7.
112. Kim J., et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-amyloidosis. J. Neurosci. 2011, 31:18007-18012.
113. Kimura H., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000, 95:189-197.
114. Koedam E.L., et al. Early-versus late-onset Alzheimer's disease: more than age alone. J. Alzheimers Dis. 2010, 19:1401-1408.
115. Koppenol W.H. The Haber-Weiss cycle-70 years later. Redox Rep. 2001, 6:229-234.
116. Kövari E., Herrmann F.R., Hof P.R., Bouras C. The relationship between cerebral amyloid angiopathy and cortical microinfarcts in brain ageing and Alzheimer's disease. Neuropathol. Appl. Neurobiol. 2013, 39:498-509.
117. Kristinsson J., Snaedal J., Tórsdóttir G., Jóhannesson T. Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies. Neuropsychiatr. Dis. Treat. 2012, 8:515-521.
118. Kudin A.P., Bimpong-Buta N.Y.B., Vielhaber S., Elger C.E., Kunz W.S. Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem. 2004, 279:4127-4135.
119. Kummer M.P., et al. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron 2011, 71:833-844.
120. Kurata T., et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res. 2011, 1371:161-170.
121. Kusminski C.M., et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 2012, 18:1539-1549.
122. Lacor P.N., et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24:10191-10200.
123. LaDu M.J., et al. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 1994, 269:23403-23406.
124. Lane D.J.R., Robinson S.R., Czerwinska H., Bishop G.M., Lawen A. Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. Biochem. J. 2010, 432:123-132.
125. Lee M., et al. Upregulation of haptoglobin in reactive astrocytes after transient forebrain ischemia in rats. J. Cereb. Blood Flow Metab. 2002, 22:1176-1180.
126. Lei P., et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 2012, 18:291-295.
127. Leskovjan A.C., Kretlow A., Lanzirotti A., Miller L.M. Synchrotron-based imaging detects metal and plaques in a mouse model of Alzheimer's disease. Bioeng. Proc. Northeast Conf. 2007, 54-55. 10.1109/NEBC.2007.4413276.
128. Leskovjan A.C., et al. Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer's disease. NeuroImage 2011, 55:32-38.
129. Li J., et al. Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J. Biol. Chem. 2012, 287:44593-44601.
130. Liao C.R., et al. Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. Analyst 2013, 138:3991-3997.
131. Loeffler D.A., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 1995, 65:710-724.
132. Lowenstein C.J., Dinerman J.L., Snyder S.H. Nitric oxide: a physiologic messenger. Ann. Intern. Med. 1994, 120:227-237.
133. Lu F., Li X., Suo A.Q., Zhang J.W. Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin. Chin. Med. J. (Engl.) 2010, 123:1864-1870.
134. 2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat. Med. 2007, 13:448-454.
135. Lundgaard I., Osório M.J., Kress B.T., Sanggaard S., Nedergaard M. White matter astrocytes in health and disease. Neuroscience 2014, 276:161-173.
136. Macara I.G., Hoy T.G., Harrison P.M. The formation of ferritin from apoferritin. Kinetics and mechanism of iron uptake. Biochem. J. 1972, 126:151-162.
137. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240(80-):622-630.
138. Mairuae N., Hall E.C., Cheepsunthorn P., Lee S.Y., Connor J.R. The H63D HFE gene variant promotes activation of the intrinsic apoptotic pathway via mitochondria dysfunction following β-amyloid peptide exposure. J. Neurosci. Res. 2010, 88:3079-3089.
139. Majumdar A., et al. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell 2007, 18:1490-1496.
140. Makarov P., Kropf S., Wiswedel I., Augustin W., Schild L. Consumption of redox energy by glutathione metabolism contributes to hypoxia/reoxygenation-induced injury in astrocytes. Mol. Cell. Biochem. 2006, 286:95-101.
141. Manook A., et al. Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012, 7:e31310.
142. Manson J., et al. The prion protein gene: a role in mouse embryogenesis?. Development 1992, 115:117-122.
143. Mapstone M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20:415-418.
144. Mariani S., et al. Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. Front. Aging Neurosci. 2013, 5:37.
145. Mathiisen T.M., Lehre K.P., Danbolt N.C., Ottersen O.P. The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 2010, 58:1094-1103.
146. Maynard C.J., et al. Overexpression of Alzheimer's disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 2002, 277:44670-44676.
147. McCarthy R.C., Park Y.-H., Kosman D.J. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep. 2014, 15:809-815.
148. McLachlan D.R., Smith W.L., Kruck T.P. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther. Drug Monit. 1993, 15.
149. Meadowcroft M.D., Connor J.R., Smith M.B., Yang Q.X. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 2009, 29:997-1007.
150. Meier-Ruge W., Ulrich J., Brühlmann M., Meier E. Age-related white matter atrophy in the human brain. Ann. N. Y. Acad. Sci. 1992, 673:260-269.
151. Merlini M., Meyer E.P., Ulmann-Schuler A., Nitsch R.M. Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice. Acta Neuropathol. 2011, 122:293-311.
152. Methia N., et al. ApoE deficiency compromises the blood brain barrier especially after injury. Mol. Med. 2001, 7:810-815.
153. Meyer E.P., Ulmann-Schuler A., Staufenbiel M., Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3587-3592.
154. Misiti F., Carelli-Alinovi C., Sampaolese B., Giardina B. Beta-amyloid decreases detectable endothelial nitric oxide synthase in human erythrocytes: a role for membrane acetylcholinesterase. Cell Biochem. Funct. 2012, 30:474-479.
155. Mladenka P., Simůnek T., Hübl M., Hrdina R. The role of reactive oxygen and nitrogen species in cellular iron metabolism. Free Radic. Res. 2006, 40:263-272.
156. Moloney A.M., et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
157. Moos T., Morgan E.H. Transferrin and transferrin receptor function in brain barrier systems. Cell. Mol. Neurobiol. 2000, 20:77-95.
158. Moos T., Rosengren Nielsen T., Skjørringe T., Morgan E.H. Iron trafficking inside the brain. J. Neurochem. 2007, 103:1730-1740.
159. Morikawa M., et al. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β. Neurobiol. Dis. 2005, 19:66-76.
160. Morris C.M., Candy J.M., Kerwin J.M., Edwardson J.A. Transferrin receptors in the normal human hippocampus and in Alzheimer's disease. Neuropathol. Appl. Neurobiol. 1994, 20:473-477.
161. Moser M., Colello R.J., Pott U., Oesch B. Developmental expression of the prion protein gene in glial cells. Neuron 1995, 14:509-517.
162. Muckenthaler M.U., Galy B., Hentze M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 2008, 28:197-213.
163. Mullan M., et al. Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology. Am. J. Med. Genet. 1993, 48:129-130.
164. Muñoz P., et al. Effect of iron on the activation of the MAPK/ERK pathway in PC12 neuroblastoma cells. Biol. Res. 2006, 39:189-190.
165. Nakamura T., Lipton S.A. S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid. Redox Signal. 2011, 14:1479-1492.
166. Nandar W., Neely E.B., Unger E., Connor J.R. A mutation in the HFE gene is associated with altered brain iron profiles and increased oxidative stress in mice. Biochim. Biophys. Acta Mol. Basis Dis. 2013, 1832:729-741.
167. Nave K.-A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci. 2010, 11:275-283.
168. Needham E., Ciccotosto G.D., Cappai R. Combined deletions of amyloid precursor protein and amyloid precursor-like protein 2 reveals different effects on mouse brain metal homeostasis. Metallomics 2014, 598-603. 10.1039/c3mt00358b.
169. Nemeth E., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
170. Nicolas G., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 2002, 110:1037-1044.
171. Pardridge W.M., Eisenberg J., Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987, 36:892-895.
172. Parys B., C0d4té A., Gallo V., De Koninck P., Sík A. Intercellular calcium signaling between astrocytes and oligodendrocytes via gap junctions in culture. Neuroscience 2010, 167:1032-1043.
173. Pelizzoni I., Zacchetti D., Campanella A., Grohovaz F., Codazzi F. Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. Biochim. Biophys. Acta 2013, 1832:1326-1333.
174. Pelizzoni I., Zacchetti D., Campanella A., Grohovaz F., Codazzi F. Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. Biochim. Biophys. Acta Mol. Basis Dis. 2013, 1832:1326-1333.
175. Petzold A., et al. Cerebrospinal fluid ferritin level, a sensitive diagnostic test in late-presenting subarachnoid hemorrhage. J. Stroke Cerebrovasc. Dis. 2011, 20:489-493.
176. Piloni N.E., Fermandez V., Videla L.A., Puntarulo S. Acute iron overload and oxidative stress in brain. Toxicology 2013, 314:174-182.
177. Piñero D.J., Hu J., Connor J.R. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell. Mol. Biol. 2000, 46:761-776.
178. Pinilla-Tenas J.J., et al. Zip14 is a complex broad-scope metal-ion transporter whose functional properties support roles in the cellular uptake of zinc and nontransferrin-bound iron. Am. J. Physiol. Cell Physiol. 2011, 301:C862-C871.
179. Popp J., et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem. Pharmacol. 2013, 86:37-42.
180. Prasanthi J.R.P., et al. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J. Alzheimers Dis. 2012, 30:167-182.
181. Prior M., Dargusch R., Ehren J.L., Chiruta C., Schubert D. The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res. Ther. 2013, 5:25.
182. Quintana C., et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 2006, 153:42-54.
183. Radlowski E.C., Johnson R.W. Perinatal iron deficiency and neurocognitive development. Front. Hum. Neurosci. 2013, 7:11.
184. Raffai R.L., Weisgraber K.H. Cholesterol: from heart attacks to Alzheimer's disease. J. Lipid Res. 2003, 44:1423-1430.
185. Raha A.A., Vaishnav R.A., Friedland R.P., Bomford A., Raha-Chowdhury R. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathol. Commun. 2013, 1:55.
186. Raji C.A., et al. White matter lesions and brain gray matter volume in cognitively normal elders. Neurobiol. Aging 2012, 33:834.e7-834.e16.
187. Rakic P., Bourgeois J.P., Eckenhoff M.F., Zecevic N., Goldman-Rakic P.S. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science 1986, 232:232-235.
188. Randolph C., Karantzoulis S., Guskiewicz K. Prevalence and characterization of mild cognitive impairment in retired National Football League players. J. Int. Neuropsychol. Soc. 2013, 19:873-880.
189. Rathnasamy G., Ling E.-A., Kaur C. Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular white matter through production of proinflammatory cytokines and reactive oxygen/nitrogen species. J. Neurosci. 2011, 31:17982-17995.
190. Raven E.P., Lu P.H., Tishler T.A., Heydari P., Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J. Alzheimers Dis. 2013, 37:127-136.
191. Reilly J.F., et al. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4837-4842.
192. Reynolds M.R., et al. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. J. Neurosci. 2006, 26:10636-10645.
193. Richardson D.R. Mysteries of the transferrin-transferrin receptor 1 interaction uncovered. Cell 2004, 116:483-485.
194. Rogers J.T., et al. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277:45518-45528.
195. Roth G.M., Sun B., Greensite F.S., Lott I.T., Dietrich R.B. Premature aging in persons with Down syndrome: MR findings. Am. J. Neuroradiol. 1996, 17:1283-1289.
196. Roth A.D., Ramírez G., Alarcón R. Oligodendrocytes Damage in Alzheimer's Disease: Beta Amyloid Toxicity and Inflammation 2005, 381-387.
197. Rottkamp C.A., et al. Redox-active iron mediates amyloid-β toxicity. Free Radic. Biol. Med. 2001, 30:447-450.
198. Rouault T.A. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14:551-564.
199. Rovira C., Carloni P. The iron-sulfur bond in cytochrome c. J. Phys. Chem. B 1999, 103:7031-7035.
200. Sano M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 1997, 336:1216-1222.
201. Sasaki T., et al. Visualization of mitochondrial oxygen fixation in brain slices by gas-tissue autoradiography. Brain Res. 1999, 831:263-272.
202. Saunders A.M., et al. Association of apolipoprotein-E allele epsilon-4 with late-onset familial and sporadic Alzheimers-disease. Neurology 1993, 43:1467-1472.
203. Savory J., Huang Y., Wills M.R., Herman M.M. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease. Neurotoxicology 1998, 19:209-214.
204. Scarmeas N., Stern Y., Tang M.-X., Mayeux R., Luchsinger J.A. Mediterranean diet and risk for Alzheimer's disease. Ann. Neurol. 2006, 59:912-921.
205. Schneider A., Schulz-Schaeffer W., Hartmann T., Schulz J.B., Simons M. Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiol. Dis. 2006, 23:573-577.
206. Schoenemann P.T., Sheehan M.J., Glotzer L.D. Prefrontal white matter volume is disproportionately larger in humans than in other primates. Nat. Neurosci. 2005, 8:242-252.
207. Schrag M., Mueller C., Oyoyo U., Smith M.A., Kirsch W.M. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog. Neurobiol. 2011, 94:296-306.
208. Schrag M., et al. Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease. J. Alzheimers Dis. 2011, 24:137-149.
209. Schulz K., Kroner A., David S. Iron efflux from astrocytes plays a role in remyelination. J. Neurosci. 2012, 32:4841-4847.
210. Sheftel A.D., Mason A.B., Ponka P. The long history of iron in the universe and in health and disease. Biochim. Biophys. Acta Gen. Subj. 2012, 1820:161-187.
211. Sherriff F.E., Bridges L.R., Sivaloganathan S. Early detection of axonal injury after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta Neuropathol. 1994, 87:55-62.
212. Sherwood C.C., et al. Aging of the cerebral cortex differs between humans and chimpanzees. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13029-13034.
213. Shi Y., Ghosh M., Kovtunovych G., Crooks D.R., Rouault T.A. Both human ferredoxins 1 and 2 and ferredoxin reductase are important for iron-sulfur cluster biogenesis. Biochim. Biophys. Acta, Mol. Cell Res. 2012, 1823:484-492.
214. Sidera C., Parsons R., Austen B. The regulation of beta-secretase by cholesterol and statins in Alzheimer's disease. J. Neurol. Sci. 2005, 229-230:269-273.
215. Singh N. The role of iron in prion disease and other neurodegenerative diseases. PLoS Pathog. 2014, 10:e1004335.
216. Singh A., et al. Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog. 2009, 5.
217. Singh A., et al. Prion protein regulates iron transport by functioning as a ferrireductase. J. Alzheimers Dis. 2013, 35:541-552.
218. Skaper S.D., et al. Oligodendrocytes are a novel source of amyloid peptide generation. Neurochem. Res. 2009, 34:2243-2250.
219. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9866-9868.
220. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009, 28:75-80.
221. Spagnuolo M.S., et al. Haptoglobin interacts with apolipoprotein e and beta-amyloid and influences their crosstalk. ACS Chem. Neurosci. 2014, 5:837-847.
222. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
223. Steele M.L., Robinson S.R. Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol. Aging 2012, 33:423.e1-423.e13.
224. Steinert J.R., et al. Nitric oxide is an activity-dependent regulator of target neuron intrinsic excitability. Neuron 2011, 71:291-305.
225. Su Y., Chang P.T. Acidic pH promotes the formation of toxic fibrils from β-amyloid peptide. Brain Res. 2001, 893:287-291.
226. Suzuki A., et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011, 144:810-823.
227. Takeda A. Essential trace metals and brain function. Yakugaku Zasshi 2004, 124:577-585.
228. Tasdemir-Yilmaz O.E., Freeman M.R. Astrocytes engage unique molecular programs to engulf pruned neuronal debris from distinct subsets of neurons. Genes Dev. 2014, 28:20-33.
229. Togo T., Katsuse O., Iseki E. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol. Res. 2004, 26:563-566.
230. Um H.C., Jang J.H., Kim D.H., Lee C., Surh Y.J. Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells. Nitric Oxide Biol. Chem. 2011, 25:161-168.
231. Um J.W., et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012, 15:1227-1235.
232. Urrutia P., et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 2013, 126:541-549.
233. Urrutia P.J., Mena N.P., Núñez M.T. The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol. 2014, 5. (MAR).
234. Vaquero M.P., et al. Mineral and vitamin status in elderly persons from Northwest Spain consuming an Atlantic variant of the Mediterranean diet. Ann. Nutr. Metab. 2004, 48:125-133.
235. Verghese P.B., et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1807-E1816.
236. Wahrle S., et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 2002, 9:11-23.
237. White A.R., et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 1999, 842:439-444.
238. Wiesener M.S., et al. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J. 2003, 17:271-273.
239. Wilcock D.M., Vitek M.P., Colton C.A. Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience 2009, 159:1055-1069.
240. Wiley S.E., Murphy A.N., Ross S.A., van der Geer P., Dixon J.E. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5318-5323.
241. Wilkinson N., Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front. Pharmacol. 2014, 5:176.
242. Wilkinson B.L., et al. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol. Aging 2012, 33.
243. Wong B.X., et al. β-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS One 2014, 9:e114174.
244. Xie L., et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
245. Xu J., et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci. 2001, 21:RC118.
246. Yakes F.M., Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. 1997, 94:514-519.
247. Yamamoto A., et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 2004, 82:1137-1147.
248. Zecca L., et al. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 2008, 62:1097-1101.
249. Zhang X., et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 2007, 282:10873-10880.
250. Zhao J., O'Connor T., Vassar R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J. Neuroinflammation 2011, 8:150.
251. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28:202-208.